We have previously demonstrated the potential beneficial effects of Lovastatin, a competitive inhibitor of the 3-Hydroxy-Methyl-Glutaryl-CoA reductase (HMG-CoA reductase), the first enzyme from the cholesterol synthesis pathway, in gastric cancer. Here, HMGCR is linked to gastric cancer.